文献速递基础与转化研究临床试验与 GCP

应用「快速失败」方法评估κ阿片受体拮抗剂治疗快感缺失的随机机制验证试验

A randomized proof-of-mechanism trial applying the 'fast-fail' approach to evaluating κ-opioid antagonism as a treatment for anhedonia.
PubMed 文献 · Nat Med · 2020-03-30

本研究首次全面应用美国国家精神卫生研究所(NIMH)的「快速失败」方法,在多中心、8周、双盲、安慰剂对照随机试验中,评估选择性κ阿片受体(KOR)拮抗剂JNJ-67953964(10 mg)对伴有情绪或焦虑障碍的快感缺失患者的机制验证效果。结果显示,与安慰剂相比,JNJ-67953964显著增加奖励预期期间fMRI腹侧纹状体激活(主要结局),且总体耐受良好,无严重不良事件。研究支持继续评估靶点占位的临床影响,并为实施「快速失败」方法提供了模型。

要点

  • JNJ-67953964显著增加奖励预期期间腹侧纹状体fMRI激活,效应量0.58。
  • JNJ-67953964总体耐受良好,未报告严重不良事件。
  • 研究支持推进靶点占位临床影响评估,验证「快速失败」方法可行性。

核心结论

  • 选择性KOR拮抗剂JNJ-67953964在快感缺失患者中显著增加奖励预期相关的腹侧纹状体激活,支持推进其临床影响评估。

研究设计与样本

  • 多中心、8周、双盲、安慰剂对照、随机试验,纳入伴有情绪或焦虑障碍的快感缺失患者。
  • JNJ-67953964 10 mg组n=45,安慰剂组n=44。

主要发现

  • 主要结局奖励预期期间fMRI腹侧纹状体激活:JNJ-67953964组基线校正均值0.72(s.d.=0.67),安慰剂组0.33(s.d.=0.68),F(1,86)=5.58,P<0.01,效应量0.58(95%CI 0.13-0.99)。
  • JNJ-67953964总体耐受良好,未报告严重不良事件。

关键数值与推荐

  • 主要结局为奖励预期期间fMRI腹侧纹状体激活,JNJ-67953964较安慰剂显著增加(P<0.01)。
  • 效应量0.58(95%CI 0.13-0.99)。

临床怎么用

  • 「快速失败」方法通过生物标志物机制验证为早期药物开发提供决策依据。
  • KOR拮抗可能作为快感缺失的潜在治疗靶点,需进一步临床影响评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The National Institute of Mental Health (NIMH) 'fast-fail' approach seeks to improve too-often-misleading early-phase drug development methods by incorporating biomarker-based proof-of-mechanism (POM) testing in phase 2a. This first comprehensive application of the fast-fail approach evaluated the potential of κ-opioid receptor (KOR) antagonism for treating anhedonia with a POM study determining whether robust target engagement favorably impacts the brain circuitry hypothesized to mediate clinical effects. Here we report the results from a multicenter, 8-week, double-blind, placebo-controlled, randomized trial in patients with anhedonia and a mood or anxiety disorder (selective KOR antagonist (JNJ-67953964, 10 mg; n = 45) and placebo (n = 44)). JNJ-67953964 significantly increased functional magnetic resonance imaging (fMRI) ventral striatum activation during reward anticipation (primary outcome) as compared to placebo (baseline-adjusted mean: JNJ-67953964, 0.72 (s.d. = 0.67); placebo, 0.33 (s.d. = 0.68); F(1,86) = 5.58, P < 0.01; effect size = 0.58 (95% confidence interval, 0.13-0.99)). JNJ-67953964, generally well tolerated, was not associated with any serious adverse events. This study supports proceeding with assessment of the clinical impact of target engagement and serves as a model for implementing the 'fast-fail' approach.

来源:Nat Med,查看原文。版权归原作者所有。

引用

  1. Krystal AD, Pizzagalli DA, Smoski M, et al. A randomized proof-of-mechanism trial applying the 'fast-fail' approach to evaluating κ-opioid antagonism as a treatment for anhedonia. Nat Med. 2020. PMID: 32231295. doi:10.1038/s41591-020-0806-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。